Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aeras and CanSino to Collaborate on TB Vaccine Development

publication date: May 5, 2012

Tianjin CanSino Biotechnology Inc. and Aeras, a US-based non-profit, today announced a collaboration to advance the development of CanSino’s tuberculosis vaccine candidate. TB continues to be a major threat to global health, causing 1.4 million deaths worldwide annually. According to the terms of the agreement, Aeras will provide financial and technical support for CanSino’s non-human primate proof-of-concept study in China. More details…

Share this with colleagues:   



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital